Lifecore Biomedical, Inc. filings document the reporting obligations of a Nasdaq-listed injectables CDMO that develops, fills and finishes sterile pharmaceutical products and manufactures injectable-grade hyaluronic acid. Its 8-K reports furnish operating results, financial-condition updates and Regulation FD investor presentation materials tied to the company’s CDMO programs and corporate updates.
Proxy and governance filings cover director elections, annual meeting voting, executive compensation, incentive plan matters, shareholder proposal procedures and the company’s fiscal-year change to calendar-year reporting. The filings also reference the company’s common stock and Series A Convertible Preferred Stock within voting and capital-structure disclosures.
Lifecore Biomedical reports a weak quarter with revenue of $23,193 (thousands), down 34% from $35,154 (thousands), and a net loss of $14,980 (thousands). Gross margin compressed to 19.2% from 28.0% as HA manufacturing sales fell sharply and CDMO volumes declined.
Operating expenses dropped 52% to $9,134 (thousands) mainly because the prior year included a $6,851 (thousands) loss on asset sales and higher legal and professional fees. However, interest expense and the non‑cash loss from the Alcon debt derivative increased, keeping the company in a sizable loss.
Cash was $20,795 (thousands) with $17,300 (thousands) available on the revolver, while total debt principal reached $200,062 (thousands), including $188,627 (thousands) under the Alcon term loan. Redeemable preferred stock carried a $49,263 (thousands) liquidation preference and can be put to the company for cash redemption starting June 29, 2026.
Lifecore Biomedical, Inc. reported first-quarter 2026 revenue of $23.2 million, down 34% from $35.2 million in the comparable 2025 quarter, as both CDMO and hyaluronic acid manufacturing sales declined. Gross margin fell to 19% from 28%, while operating expenses dropped 52% to $9.1 million, reflecting cost containment.
The company posted a net loss of $15.0 million, or $0.43 per diluted share, similar to the prior period’s $14.8 million loss. Adjusted EBITDA was $1.0 million, down from $5.7 million. Cash from operations improved to $4.7 million and free cash flow reached $3.6 million, supported by lower capital spending.
Lifecore ended the quarter with $38.1 million of liquidity, including $20.8 million of cash and $17.3 million of revolver availability. Management reaffirmed 2026 guidance for revenue of $120–$125 million and Adjusted EBITDA of $20.5–$25 million, and highlighted three new commercial site transfer wins, ongoing margin initiatives, and the January 2026 launch of a new ERP system.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 1,867,916 shares of LifeCore Biomedical, Inc. common stock, representing 4.98% of the class. The filing states the stake reflects securities held by certain Reporting Business Units of BlackRock, Inc.
The cover lists CUSIP 514766104 and an address for the issuer; the amendment was signed by Spencer Fleming, Managing Director, on 04/27/2026.
Lifecore Biomedical executive Thomas D. Salus reported a routine tax-related share disposition. On April 14, 2026, 24,645 shares of common stock were withheld by the company at $5.20 per share to cover tax obligations from vesting restricted stock units. After this withholding, Salus directly owned 246,333 shares of Lifecore Biomedical common stock, indicating he retained a substantial equity position and that no open-market sale occurred.
Lifecore Biomedical, Inc. reported strong improvement for the seven‑month transition period ended December 31, 2025, with revenue of $75.5 million, up 20% from $63.0 million in the comparable 2024 period. Gross margin rose to 31% from 26%, while operating expenses fell to $24.4 million, a 31% reduction from $35.6 million. Net loss narrowed to $18.0 million from $30.6 million, and Adjusted EBITDA increased to $13.1 million from $2.6 million, with free cash flow of $3.6 million versus a prior use of $11.8 million. Lifecore ended the quarter with $38.9 million of liquidity, including $17.5 million of cash and $21.4 million of revolver availability.
For 2026, the company guides to revenue of $120–$125 million and a GAAP net loss of $(33.4)–$(28.9) million, compared with pro forma 2025 revenue of $141.4 million and a net loss of $(26.0) million. 2026 Adjusted EBITDA is projected at $20.5–$25.0 million versus pro forma 2025 Adjusted EBITDA of $30.1 million. The balance sheet shows total assets of $232.2 million and total liabilities of $198.1 million, with stockholders’ equity at $(14.2) million.
The capital structure includes Series A Redeemable Convertible Preferred Stock with an aggregate liquidation preference of $50.2 million as of June 29, 2026; holders may demand redemption from that date, and unpaid amounts accrue interest at 1.0% per month. Under Lifecore’s term loan with Alcon Research, LLC, interest is currently payable‑in‑kind, but starting in May 2026, 3% per year becomes payable in cash through maturity in May 2029, with the remaining 7% continuing as payable‑in‑kind. Management targets a 12% revenue CAGR from 2025–2029 and EBITDA margins above 25% over the mid‑term, supported by expanded capacity, new customer programs, and an ERP system launched in January 2026 intended to improve efficiency.
Lifecore Biomedical, Inc. is aligning its corporate calendar with the calendar year after previously changing its fiscal year to end on December 31 for the period from May 26, 2025 to December 31, 2025. The company also plans to align its Annual Meetings and proxy filings with typical calendar-year reporting practices.
The Board has set June 4, 2026 as the date of the 2026 Annual Meeting of Stockholders. Because this is more than 30 days earlier than the prior year’s October 29, 2025 meeting, shareholder proposals and director nominations must be received by March 16, 2026 and must meet all requirements under SEC rules, the company’s Bylaws, and Delaware law.
Lifecore Biomedical’s Chief Legal & Administration officer, Thomas D. Salus, was granted an equity award reported as 30,000 shares of common stock at a price of $0.00 per share. This represents a grant, award, or other acquisition rather than an open-market purchase.
Footnotes explain that the award consists of restricted stock units that convert into common stock of Lifecore Biomedical, Inc. on a 1-for-1 basis. These restricted stock units will vest on the third anniversary of the grant date. Following this award, Salus directly holds 270,978 shares.
BlackRock, Inc. has disclosed a passive ownership stake in Lifecore Biomedical, Inc., reporting beneficial ownership of 1,899,903 shares of common stock, representing 5.1% of the class as of 12/31/2025. BlackRock reports sole power to vote 1,876,400 of these shares and sole power to dispose of all 1,899,903 shares, with no shared voting or dispositive power.
The filing clarifies that the stake is held through certain BlackRock business units in the ordinary course of business and is not held for the purpose of changing or influencing control of Lifecore Biomedical. Various underlying clients and investors have rights to dividends or sale proceeds, but no single such person has more than five percent of Lifecore’s outstanding common shares.
Lifecore Biomedical, Inc. reported that its Compensation Committee approved and adopted a new Incentive Bonus Plan effective January 14, 2026. The plan covers executive officers and certain other employees chosen by the committee and provides for cash bonus payments based on achieving financial and other performance targets.
The committee has broad authority under the plan to select participants, set performance periods, choose and weight performance goals, determine bonus amounts, link payouts to the level of goal achievement, and adjust awards for unusual events such as acquisitions or divestitures. The full text of the Incentive Bonus Plan is filed as Exhibit 10.1 to the report.